Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS)

dc.contributor.authorPerreault, L.
dc.contributor.authorPan, Q.
dc.contributor.authorAroda, V. R.
dc.contributor.authorBarrett-Connor, E.
dc.contributor.authorDabelea, D.
dc.contributor.authorDagogo-Jack, S.
dc.contributor.authorHamman, R. F.
dc.contributor.authorKahn, S. E.
dc.contributor.authorMather, Kieren J.
dc.contributor.departmentDepartment of Medicine, School of Medicineen_US
dc.date.accessioned2017-10-06T15:18:35Z
dc.date.available2017-10-06T15:18:35Z
dc.date.issued2017
dc.description.abstractAim Approximately half of the participants in the Diabetes Prevention Outcomes Study (DPPOS) had diabetes after 15 years of follow-up, whereas nearly all the others remained with pre-diabetes. We examined whether formerly unexplored factors in the DPPOS coexisted with known risk factors that posed additional risk for, or protection from, diabetes as well as microvascular disease. Methods Cox proportional hazard models were used to examine predictors of diabetes. Sequential modelling procedures considered known and formerly unexplored factors. We also constructed models to determine whether the same unexplored factors that associated with progression to diabetes also predicted the prevalence of microvascular disease. Hazard ratios (HR) are per standard deviation change in the variable. Results In models adjusted for demographics and known diabetes risk factors, two formerly unknown factors were associated with risk for both diabetes and microvascular disease: number of medications taken (HR = 1.07, 95% confidence intervals (95% CI) 1.03 to 1.12 for diabetes; odds ratio (OR) = 1.10, 95% CI 1.04 to 1.16 for microvascular disease) and variability in HbA1c (HR = 1.02, 95% CI 1.01 to 1.03 for diabetes; OR = 1.06, 95% CI 1.04 to 1.09 for microvascular disease per sd). Total comorbidities increased risk for diabetes (HR = 1.10, 95% CI 1.04 to 1.16), whereas higher systolic (OR = 1.22, 95% CI 1.13 to 1.31) and diastolic (OR = 1.14, 95% CI 1.05 to 1.22) blood pressure, as well as the use of anti-hypertensives (OR = 1.41, 95% CI 1.23 to 1.62), increased risk of microvascular disease. Conclusions Several formerly unexplored factors in the DPPOS predicted additional risk for diabetes and/or microvascular disease – particularly hypertension and the use of anti-hypertensive medications – helping to explain some of the residual disease risk in participants of the DPPOS.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationPerreault, L., Pan, Q., Aroda, V. R., Barrett-Connor, E., Dabelea, D., Dagogo-Jack, S., Hamman, R. F., Kahn, S. E., Mather, K. J., Knowler, W. C. and The Diabetes Prevention Program Research Group (2017), Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabet. Med.. Accepted Author Manuscript. doi:10.1111/dme.13453en_US
dc.identifier.urihttps://hdl.handle.net/1805/14261
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1111/dme.13453en_US
dc.relation.journalDiabetic Medicineen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectDPPOSen_US
dc.subjectresidual risken_US
dc.subjectdiabetesen_US
dc.titleExploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS)en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Perreault_2017_exploring.pdf
Size:
622.14 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: